H-11047: a study of PS-341 [bortezomib] followed by radical prostatectomy for patients with adenocarcinoma of the prostate (spore: 11-01-30-13).

Trial Profile

H-11047: a study of PS-341 [bortezomib] followed by radical prostatectomy for patients with adenocarcinoma of the prostate (spore: 11-01-30-13).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Jul 2008 The expected completion date for this trial is 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top